Literature DB >> 22699849

Anatomic and clinical pathology of cognitive impairment and dementia.

Kathleen S Montine1, Thomas J Montine.   

Abstract

Progressive cognitive impairment and its clinical culmination in dementia loom as a major public health problem in the coming generation of older adults, and this fact compels investigation to develop interventions that prevent, delay, or cure. The tools of anatomic pathology have provided key insights into the complex convergence of multiple diseases that commonly contribute to the dementia syndrome and its prodrome in the community setting, and they have suggested some exposures that may modulate disease burden. The tools of clinical pathology, in combination with neuroimaging, have revolutionized the approach to clinical investigation of Alzheimer's disease and are now doing the same with Lewy body disease and vascular brain injury. The tools of anatomic and clinical pathology will continue to contribute to our understanding of these diseases as we advance toward effective interventions for the diseases that commonly cause cognitive impairment and dementia in older adults.

Entities:  

Mesh:

Year:  2013        PMID: 22699849      PMCID: PMC3686298          DOI: 10.3233/JAD-2012-129032

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  16 in total

1.  Late-life dementias: does this unyielding global challenge require a broader view?

Authors:  Thomas J Montine; Eric B Larson
Journal:  JAMA       Date:  2009-12-16       Impact factor: 56.272

2.  Population-based neuropathology: the best of times.

Authors:  Eric B Larson
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

3.  Ecology of the aging human brain.

Authors:  Joshua A Sonnen; Karen Santa Cruz; Laura S Hemmy; Randall Woltjer; James B Leverenz; Kathleen S Montine; Clifford R Jack; Jeffrey Kaye; Kelvin Lim; Eric B Larson; Lon White; Thomas J Montine
Journal:  Arch Neurol       Date:  2011-08

4.  Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Authors:  Fadi Abdi; Joseph F Quinn; Joseph Jankovic; Martin McIntosh; James B Leverenz; Elaine Peskind; Randy Nixon; John Nutt; Katherine Chung; Cyrus Zabetian; Ali Samii; Melanie Lin; Stephen Hattan; Catherine Pan; Yan Wang; Jinghua Jin; David Zhu; G Jane Li; Yan Liu; Dana Waichunas; Thomas J Montine; Jing Zhang
Journal:  J Alzheimers Dis       Date:  2006-08       Impact factor: 4.472

5.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

6.  Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques.

Authors:  J A Sonnen; E B Larson; R L Walker; S Haneuse; P K Crane; S L Gray; J C S Breitner; T J Montine
Journal:  Neurology       Date:  2010-09-01       Impact factor: 9.910

7.  Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

Authors:  R Motter; C Vigo-Pelfrey; D Kholodenko; R Barbour; K Johnson-Wood; D Galasko; L Chang; B Miller; C Clark; R Green
Journal:  Ann Neurol       Date:  1995-10       Impact factor: 10.422

8.  Dementia and Alzheimer disease incidence: a prospective cohort study.

Authors:  Walter A Kukull; Roger Higdon; James D Bowen; Wayne C McCormick; Linda Teri; Gerard D Schellenberg; Gerald van Belle; Lance Jolley; Eric B Larson
Journal:  Arch Neurol       Date:  2002-11

9.  Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

Authors:  M Vandermeeren; M Mercken; E Vanmechelen; J Six; A van de Voorde; J J Martin; P Cras
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

10.  Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases.

Authors:  Hanae Nakashima-Yasuda; Kunihiro Uryu; John Robinson; Sharon X Xie; Howard Hurtig; John E Duda; Steven E Arnold; Andrew Siderowf; Murray Grossman; James B Leverenz; Randy Woltjer; Oscar L Lopez; Ronald Hamilton; Debby W Tsuang; Douglas Galasko; Eliezer Masliah; Jeffrey Kaye; Christopher M Clark; Thomas J Montine; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2007-07-25       Impact factor: 17.088

View more
  5 in total

1.  Differences in Cognitive Impairment in Primary Age-Related Tauopathy Versus Alzheimer Disease.

Authors:  Lilah M Besser; Charles Mock; Merilee A Teylan; Jason Hassenstab; Walter A Kukull; John F Crary
Journal:  J Neuropathol Exp Neurol       Date:  2019-03-01       Impact factor: 3.685

Review 2.  The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline.

Authors:  Roderick A Corriveau; Francesca Bosetti; Marian Emr; Jordan T Gladman; James I Koenig; Claudia S Moy; Katherine Pahigiannis; Salina P Waddy; Walter Koroshetz
Journal:  Cell Mol Neurobiol       Date:  2016-04-19       Impact factor: 5.046

3.  Characterization of cognitive impairments and neurotransmitter changes in a novel transgenic mouse lacking Slc10a4.

Authors:  E J Melief; J T Gibbs; X Li; R G Morgan; C D Keene; T J Montine; R D Palmiter; M Darvas
Journal:  Neuroscience       Date:  2016-03-19       Impact factor: 3.590

4.  Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease.

Authors:  Nadia O Postupna; C Dirk Keene; Caitlin Latimer; Emily E Sherfield; Rachel D Van Gelder; Jeffrey G Ojemann; Thomas J Montine; Martin Darvas
Journal:  Lab Invest       Date:  2014-07-28       Impact factor: 5.662

Review 5.  Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence.

Authors:  Carey E Gleason; Megan Zuelsdorff; Diane C Gooding; Amy J H Kind; Adrienne L Johnson; Taryn T James; Nickolas H Lambrou; Mary F Wyman; Fred B Ketchum; Alexander Gee; Sterling C Johnson; Barbara B Bendlin; Henrik Zetterberg
Journal:  Alzheimers Dement       Date:  2021-12-06       Impact factor: 16.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.